# ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings

> **NCT04352764** · — · UNKNOWN · sponsor: **Texas Cardiac Arrhythmia Research Foundation** · enrollment: 5000 (estimated)

## Conditions studied

- Covid19

## Interventions

- **DIAGNOSTIC_TEST:** CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test

## Key facts

- **NCT ID:** NCT04352764
- **Lead sponsor:** Texas Cardiac Arrhythmia Research Foundation
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-27
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-01-31
- **Target enrollment:** 5000 (ESTIMATED)
- **Last updated:** 2020-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04352764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04352764, "ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04352764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*